24457-00-9

Basic information

• Product Name: 4,6-Di-tert-butyl-3-nitro-1,2-benzoquinone
• Synonyms: 4,6-Di-tert-butyl-3-nitro-1,2-benzoquinone
• CAS NO: 24457-00-9
• Molecular Formula: C₁₄H₁₉NO₄
• Molecular Weight: 265.3
• Mol File: 24457-00-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4,6-Di-tert-butyl-3-nitro-1,2-benzoquinone(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Di-tert-butyl-3-nitro-1,2-benzoquinone(24457-00-9)
• EPA Substance Registry System: 4,6-Di-tert-butyl-3-nitro-1,2-benzoquinone(24457-00-9)

Safety Data

• Hazardous Substances Data: 24457-00-9(Hazardous Substances Data)

Upstream product

• 90-05-1 2-methoxy-phenol 
• 732-26-3 2,4,6-tri-tert-butylphenoxol 
• 7697-37-2 nitric acid 
• 3383-21-9 3,5-di-tert-butyl-o-benzoquinone 

Relevant articles and documents

Transformations of S-substituted 5,7-dimethyl-4а,5а-diphenyl-3-thioxoperhydroimidazo[4,5-e]-1,2,4-triazin-2-ones under treatment of 1,2-benzoquinones and photochemical properties of reaction products

For the first time 5,7-di-tert-butyl-1,3-dimethyl-3a,9a-diphenyl-3,3a-dihydro-1H-benzo[5,6][1,4]dioxino[2,3-d]imidazol-2(9aH)-one 13 and complex 9 of 4,6-di-tert-butyl-3-nitrobenzene-1,2-diol with 1,3-dimethyl-4,5-diphenyl-1H-imidazol-2(3H)-one 10a were p

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Unexpected formation of 6-[benzofuran-3(2H)-ylidene]-3,3a,9,9a-tetra- hydroimidazo[4,5-e]thiazolo[3,2-b][1,2,4]triazine-2,7-dione derivative

Condensation of 4,6-di(tert-butyl)-3-nitro-1,2-benzoquinone with 1,3-dimethyl-3a,9a-diphenyl-3,3a,9,9a-tetrahydroimidazo[4,5-e]- thiazolo[3,2-b][1,2,4]triazine-2,7(1H,6H)-dione in AcOH gives a new 6-(benzofuranylidene)tetrahydroimidazo[4,5-e]thiazolo[3,2-

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.